Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication.
By Kathleen R. Merikangas, H. Akiskal, J. Angst, P. Greenberg, R. Hirschfeld, M. Petukhova, Ronald C. Kessler. Archives of General Psychiatry, 2007
2,357 citations recorded by the source corpus.
Subfields: Pharmacology, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/4bd92a03b5cb441d8c27c3e91e14687b7558a799
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pharmacology
In Psychiatry and Mental health
Citations in the corpus
- Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. (2013, background): “4% reported in the National Comorbidity Survey Replication (NCS-R) in the USA (n = 9282) (362).”
- Sex differences in anxiety and depression clinical perspectives (2014, background): “The lifetime prevalence of bipolar I disorder in the National Comorbidty Survey Replication was 0.8% in men and 1.1% in women and the lifetime prevalence of bipolar II disorder is 0.9% in men and 1.3% in women (Merikangas et al., 2007).”
- Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder (2018, background): “The most common comorbid conditions are substance abuse/ dependence, anxiety disorder, personality disorder, and impulse control disorder (such as ADHD, ODD, and CD ) (45).”
- Prevalence and Correlates of Bipolar Spectrum Disorder in the World Mental Health Survey Initiative (2011, positive): “Expanding the definition of bipolarity is supported by prospective findings for a high probability of conversion to BP in youths with subthreshold mania(18) as well as by findings from the National Comorbidity Survey Replication that indicate uniform increases in spectrum of severity and impairment ”
- Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. (2009, background): “4%) for subthreshold BD (defined as recurrent hypomania without a major depressive episode or with fewer symptoms than required for threshold hypomania) (3).”
- Onset Timing, Thoughts of Self-harm, and Diagnoses in Postpartum Women With Screen-Positive Depression Findings (2013, background): “Many patients receive treatment for comorbid psychiatric disorders, but lack of recognition of the underlying bipolar disorder results in few receiving appropriate treatment.(56) Half of women with “treatment-resistant” PPD actually have bipolar disorder.”
- Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders (2014, background): “In epidemiological surveys, the lifetime comorbidity rates for any anxiety or related disorder among patients with bipolar disorder was 52% in Canada [43] and 60-75% in the US [1389,1399].”
- A Randomized Add-on Trial of an N-methyl-d-aspartate Antagonist in Treatment-Resistant Bipolar Depression (2010, result): “Compared with our previous study with ketamine in patients with treatment-resistant major depressive disorder,(34) we found (1) more rapid onset of antidepressant effects (40 vs 110 minutes), (2) a higher response rate at 40 minutes (56% vs 11%) but lower at day 1 (42% vs 71%), (3) similar remission”
- Evidence-based guidelines for treating bipolar disorder: revised third edition Recommendations from the British Association for Psychopharmacology (2009, neutral): “As defined by DSM-IV, its lifetime incidence has also been described as about 1% (I, (Angst, 1998; Merikangas et al., 2007)).”